Published in Gene Ther on June 01, 1995
Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) (2007) 0.92
Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood (2007) 0.91
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A (1996) 0.89
Genetic engineering: moral aspects and control of practice. J Assist Reprod Genet (1997) 0.75
Protecting bone marrow by gene therapy. Gene Ther (1995) 0.75
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Biochemistry and pathology of radical-mediated protein oxidation. Biochem J (1997) 3.14
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res (2000) 2.86
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene (2007) 2.79
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood (2001) 2.71
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia (2002) 2.68
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood (2000) 2.11
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood (1992) 2.07
Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood (1992) 2.05
Remember the gum-elastic bougie at extubation. J Clin Anesth (1993) 2.00
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science (1990) 1.90
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer (2010) 1.90
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia (2008) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.63
The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol (2007) 1.62
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Cytokine-regulated expression of survivin in myeloid leukemia. Blood (2001) 1.56
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood (1991) 1.56
MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia (2008) 1.53
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy (2008) 1.52
In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res (2001) 1.51
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur J Cancer (1992) 1.51
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia (2008) 1.48
Selective hepatic vascular exclusion versus Pringle manoeuvre in liver resection for tumours encroaching on major hepatic veins. Br J Surg (2012) 1.47
Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med (1999) 1.45
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia (2005) 1.44
The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood (1995) 1.44
Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol (1995) 1.42
An optimized electroporation protocol applicable to a wide range of cell lines. Biotechniques (1994) 1.39
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer (2010) 1.38
[New indications for thalidomide?]. Dtsch Med Wochenschr (2001) 1.38
Is the Wii Fit a new-generation tool for improving balance, health and well-being? A pilot study. Climacteric (2010) 1.37
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood (2000) 1.33
Apoptosis. Molecules and mechanisms. Adv Exp Med Biol (1999) 1.30
Protein hydroperoxides can give rise to reactive free radicals. Biochem J (1995) 1.30
MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia (2011) 1.30
The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia (2005) 1.30
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene (1989) 1.30
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer (2008) 1.29
Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood (1980) 1.29
The Saccharomyces cerevisiae TCM62 gene encodes a chaperone necessary for the assembly of the mitochondrial succinate dehydrogenase (complex II). J Biol Chem (1998) 1.28
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant (2009) 1.27
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia (2004) 1.24
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant (2006) 1.23
Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis (2006) 1.22
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res (2000) 1.22
Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med (2006) 1.22
Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood (1998) 1.22
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood (1995) 1.18
Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis (1995) 1.17
Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res (1996) 1.17
Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia (2003) 1.16
A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol (1988) 1.13
Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood (1994) 1.12
Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol (1999) 1.11
Changes of cellular markers during differentiation of HL-60 promyelocytes to macrophages as induced by T lymphocyte conditioned medium. Leuk Res (1981) 1.11
Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood (1996) 1.11
Effects of basic fibroblast growth factor (bFGF) on early stages of tendon healing: a rat patellar tendon model. Acta Orthop Scand (2000) 1.11
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene (2011) 1.11
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant (2006) 1.10
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol (1997) 1.10
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood (1997) 1.09
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia (2009) 1.09
Measurement of the electron charge asymmetry in pp[over ]-->W+X-->enu+X events at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 1.09
Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther (1995) 1.08
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ (2007) 1.08
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res (1999) 1.08
Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood (1999) 1.07
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer (2013) 1.06
Characterization of nuclear proteins which bind to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem (1990) 1.06
Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res (2001) 1.06
iNOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol (1998) 1.05